Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib)

NCT03975829 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT03975829
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03975829 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib)
Lead sponsor
Novartis Pharmaceuticals
Phase
Phase 4
Overall status
Active, not recruiting
Start date
November 4, 2019
Completion date
November 5, 2026
Enrollment
163 (actual)
Sites
54

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic astrocytoma, anaplastic ganglioglioma, anaplastic oligodendroglioma, anaplastic pleomorphic xanthoastrocytoma, angiocentric glioma, astrocytoma, central neurocytoma, cerebellar liponeurocytoma, chordoid glioma of third ventricle, desmoplastic infantile astrocytoma and ganglioglioma, diffuse astrocytoma, dysplastic gangliocytoma of cerebrellum, extraventricular neurocytoma, gangliocytoma, ganglioglioma, giant cell astrocytoma, glioblastoma, neurofibromatosis type 1, oligodendroglioma, childhood, papillary glioneuronal tumor, pilocytic astrocytoma, pleomorphic xanthoastrocytoma, rosette-forming glioneuronal tumor